FIELD: medicine; biotechnology.
SUBSTANCE: invention refers to biotechnology and molecular biology. Disclosed is a lentiviral vector for treating cancer, containing left (5') lentiviral LTR containing a heterologous promoter of cytomegalovirus (CMV), Psi (Ψ) a packing signal, a central polypurine path/DNA-flap (cPPT / FLAP), a rev response element (RRE); (3') lentiviral self-inactivating (SIN) LTR; a synthetic polyadenylation sequence and a polynucleotide comprising a promoter (MND) with a myeloproliferative sarcoma virus enhancer, with a negative-control portion removed, with a primer binding site substituted with a dl587rev sequence operatively linked to a nucleic acid coding a chimeric antigenic receptor (CAR).
EFFECT: invention can be used for treating cancer in medicine.
12 cl, 9 dwg, 4 tbl, 8 ex
